Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Neoantigen Derived Dendritic Cell-Based Immunotherapy as Cancer Treatment

NCT05767684 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT05767684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Neoantigen Derived Dendritic Cell-Based Immunotherapy as Cancer Treatment
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 1
Overall status
Unknown status
Start date
June 1, 2023
Completion date
March 30, 2026
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refractory tumor, solid tumor